Other substances

Atovaquone

An anti-protozoal naphtoquinone.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Atovaquone on PubChem

Marketed as

ACUVEL; ATOVAQUONE; MEPRON; WELLVONE

C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19 Preprint Screening	VERO cells			Mar/19/2020
Step toward repurposing drug discovery for COVID‐19 therapeutics through in silico approach Spike protein 3CLpro PapainLpro RdRpol nsp3 nsp16 nsp9 nsp10 nsp4 Helicase (nsp19) Small molecule In silico	in silico	1.90	Predicted to bind the SARS-CoV-2 spike protein.	Nov/10/2020

AI-suggested references

Link	Publication date
Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein.	May/13/2022
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern	Oct/18/2021
Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells	Oct/15/2021
Coronavirus disease 2019 drug discovery through molecular docking	Jun/05/2020
From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?	Jan/03/2022
Repurposing old drugs as antiviral agents for coronaviruses	May/23/2020
Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study	Nov/08/2021
Atovaquone and Berberine Chloride Reduce SARS-CoV-2 Replication In Vitro.	Dec/04/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04339426	Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection	Terminated	Phase 2	Apr/20/2020	Feb/11/2022
Alternative id - HRI-COVID-19-Anti-Malarial-001 Interventions - Drug: Atovaquone/Azithromycin Study type - Interventional Study results - No Results Available Locations - HonorHealth, Scottsdale, Arizona, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 3 Age - 18 Years to 95 Years (Adult, Older Adult) Outcome measures - Virology Cure Rate\|Incidence of GI adverse events\|Cardiac Toxicity
NCT04456153	Atovaquone for Treatment of COVID-19	Completed	Phase 2	Jul/22/2020	Jan/31/2021
Alternative id - STU-2020-0707 Interventions - Drug: Experimental Group\|Drug: Placebo Group Study type - Interventional Study results - Has Results Locations - University of Texas Medical Center, Dallas, Texas, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 60 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Primary Analysis\|Secondary Between Group Differences in Viral Load\|Change in Viral Load at Day 10 Stratified by Sex\|Percentage With 2 Log Viral Load Drop at Day 3\|Number of Participants With Change in Ordinal Scale ≥2 Points by Day 15.\|Area Under the Curve Copies/ml*Day at Day 7\|Stratifed by Remdesivir

Export (.csv)